2. Gene
  3. Il13 - interleukin 13 Gene

Il13 - interleukin 13 Gene

  • Gene
  • Protein
  • Agent
  • Ortholog
Rattus norvegicus
Gene ID: 116553 | Gene type: protein coding

About Il13

Primary_assembly 10: 37,790,130-37,792,737 reverse strand.mRatBN7.2:CM026983.1

This gene has 1 transcript (splice variant), 88 orthologues and is associated with 99 phenotypes. Restricted expression toward (RPKM 4.2).

Summary

Enables interleukin-13 receptor binding activity. Involved in several processes, including positive regulation of cell population proliferation; positive regulation of macromolecule metabolic process; and regulation of cation transmembrane transport. Located in extracellular space. Used to study asthma; extrinsic allergic alveolitis; and lipoid nephrosis. Biomarker of several diseases, including alcoholic hepatitis; middle cerebral artery infarction; peptic esophagitis; prostatic hypertrophy; and pulmonary fibrosis. Human ortholog(s) of this gene implicated in several diseases, including allergic disease (multiple); autoimmune disease (multiple); diffuse scleroderma; lung disease (multiple); and nose disease (multiple). Orthologous to human IL13 (interleukin 13). [provided by Alliance of Genome Resources, Apr 2022]

Il13 Products(1)

mRNA Protein Name
NM_053828.1 NP_446280.1 interleukin-13 precursor

Il13 Protein Structure

IL13

IL13: pfam03487 (20 - 130)

  • 0
  • 100
  • 131 a.a.
Protein Preferred Names Protein Names

interleukin-13

IL-13

T-cell activation protein P600

Recombinant Il13 Proteins

Cat. No. Product Name Accession Purity
HY-P7099 IL-13 Protein, Rat P42203 /

Related Agents

Approval
Inhibitory Antibodies (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P9926 Dupilumab Inhibitor ≥99.2% Unkown
HY-P99025 Lebrikizumab Inhibitor 99.90% Unkown
HY-P99053 Tralokinumab Inhibitor 97.59% Unkown
Clinical Phase
Inhibitory Antibodies (8)
Cat. No. Product Name Effect
Purity Phase
HY-P99496 Cendakimab Inhibitor 99.96% Phase 3
HY-P990093 Stapokibart Inhibitor 96.34% Phase 3
HY-P990090 Rademikibart Inhibitor / Phase 3
HY-P99439 Anrukinzumab Inhibitor 98.64% Phase 2
HY-P99870 Eblasakimab ≥99.0% Phase 2
HY-P99846 Dectrekumab / Phase 2
HY-P99883 Romilkimab / Phase 2
HY-P99417 Abrezekimab Inhibitor 95.00% Phase 1
Pre-clinical Phase
Bioactive Molecules (11)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-126360 Oxazolone ≥98.0% Unkown
HY-144683 PF-07038124 Inhibitor / Unkown
HY-110295 SPL-334 Inhibitor / Unkown
HY-125019 iJak-381 Inhibitor / Unkown
HY-144684 PDE4-IN-8 Inhibitor / Unkown
HY-162248 JAK1/2-IN-1 Inhibitor / Unkown
HY-RS06685 IL13 Human Pre-designed siRNA Set A / Unkown
HY-RS06686 Il13 Mouse Pre-designed siRNA Set A / Unkown
HY-RS06687 Il13 Rat Pre-designed siRNA Set A / Unkown
HY-RS06688 IL13RA1 Human Pre-designed siRNA Set A / Unkown
HY-RS06689 IL13RA2 Human Pre-designed siRNA Set A / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99238 Rolinsatamab Inhibitor 97.16% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Il13 NCBI NCBI:3596
Canis familiaris Il13 NCBI NCBI:442990
Macaca fascicularis Il13 NCBI NCBI:102125887
Mus musculus Il13 NCBI NCBI:16163